POS0814 DRUG RETENTION RATE, REASONS FOR DISCONTINUATION AND OUTCOME OF INFLIXIMAB USE IN BEHÇET SYNDROME

Background: Infliximab (IFX) plays a key role in the management of severe and refractory manifestations Behçet syndrome (BS). However we had previously shown that its sustained use may be limited due to adverse events lack patient compliance (1). Objectives: To assess retention rate IFX, events, causes discontinuation outcome after cessation IFX larger group BS patients who were followed tertiary center. Methods: The charts prescribed between 2004 2020 reviewed determine demographic features, reasons for use, previous concomitant drugs, duration, time flare following IFX. Follow-up was censored on March 2020. Results: A total 252 (195 men, mean age 40±10 years) received uveitis (n=122), vascular involvement (n=82), parenchymal neurologic (n=32), gastrointestinal (n=11), arthritis (n=10), mucocutaneous (n=4), secondary amyloidosis (n=1). Ten more than 1 requiring During median follow-up 52 (IQR: 30-88) months, 122 (48%) still receiving period 33 15-56) months while 130 (52%) discontinued 17 7-31) months. Reasons remission 25 (19%) patients, 39 (30%), efficacy 23 (18%) (4 primary 19 secondary), 36 (28%), pregnancy 4, preparation surgery 3 patients. Adverse (n=39) required infusion reaction (n=17), infection (n=7), hepatotoxicity malignancy palmoplantar psoriasis (n=3), lichen planus (n=1), drug induced lupus splenic infarction decrease left ventricular ejection fraction Among remission, 5 (20%) relapse 21, 26, 29, 38 46 remaining did not experience during 35 24-68) At end follow-up, 2 died lung adenocarcinoma treatment year, 8 years discontinuation. death with right heart failure pulmonary hypertension 1, nervous system Conclusion: Despite successful potentially organ life-threatening half our BS, long term maintenance possible 42%, mainly inefficacy. Reference: [1]Esatoglu SN, Tukek B, Taflan SS, et al. SAT0258 Drug Retention Rate Prognosis After Discontinuation Patients Syndrome. Annals Rheumatic Diseases 2020;79: 1071-1072. infliximab No (%) Number Duration (median (IQR) ) Eye 59 (48) 63 (52) Remission (n=17) Inefficacy (n=10) Lack (n=19) event (n=12) Others (n)=5) 28 (12.5-52) Vascular 82 40 (49) 42 (51) (n=7) (n=4) 18.5 (9-33.5) Parenchymal 32 21 (66) 11 (34) (n=8) (n=2) (n=1) (14.5-50) Gastrointestinal 4 (36) 7 (64) (2-17) Joint 10 (20) (80) (n=5) 20 (4-35) Mucocutaneous 6, 10, 12, 104 AA 0 6 Disclosure Interests: None declared